Loggia Nicoletta 4

What Happened

• Director Nicoletta Loggia was granted 779 shares (classified as a derivative award) of Candel Therapeutics on 2026-03-31 at a reported per-share value of $4.11, for a total reported value of $3,205. This award was granted in lieu of the normal quarterly cash payment and the underlying award was fully vested at grant.

Key Details

• Transaction date and price: 2026-03-31, 779 shares @ $4.11 each (total $3,205).
• Filing date: 2026-04-02 (filing appears timely under the 2-business-day Form 4 rule).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: award granted in lieu of quarterly cash payments; underlying award quantity fully vested at grant.
• Transaction type: Award/Grant (A); this is compensation-related, not an open-market purchase or sale.

Context

• Because the award was fully vested at grant and given instead of cash, the recipient immediately gained economic ownership in the company. Such compensation awards are routine for directors and do not necessarily indicate a buying or selling signal by the insider.